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ABSTRACT  
A sensitive, specific and rapid high-performance liquid chromatography-ultraviolet spectroscopy method was developed and successfully 
validated to estimate the repaglinide in rabbit plasma. The solvent extraction method was used for  repaglinide from serum by using ethyl 
acetate and 0.1N HCl. The mobile phase consists of acetonitrile: phosphate buffer pH 4.0 at 60:40 %v/v with 1% triethylamine at flow rate of 
0.8ml/min and at fixed wavelength of 254nm. On ten minutes of run time, repaglinide was retention at 7.4min. The extraction efficiency 95% 
for repaglinide. The intra-day and inter-day precision was in the terms of %RSD less than 1.76%. The developed method was validated and 
proposed method is useful for pharmacokinetics studies.   
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INTRODUCTION 
Repaglinide is a meglitinide antidiabetic used in the 
management of type 2 diabetes mellitus, chemically 2-
ethoxy-4-({[(1S)-3-methyl-1-[2-(piperidin-1-yl) 
phenyl]butyl]carbamoyl} methyl)benzoic acid (Fig 1). It 
reduces the fasting glucose concentrations in patients with 
type 2 diabetes mellitus. It helps to control blood sugar by 
increasing the amount of  insulin released by the pancreas. 
Repaglinide is rapidly absorbed from the gastrointestinal 
tract after oral administration. It differs from other 
antidiabetic agents in its structure, binding profile, duration 
of action and mode of excretion. Tablets containing 0.5, 1 and 
2 mg of Repaglinide are available for oral administration 
[1,2]. It is official in USP [11] which describes liquid 
chromatographic method for its quantitation. A few 
analytical methods have been reported for its quantitative 
estimation in pharmaceutical formulations and biological 
samples, which include visible spectrophotometric [3,4,5], 
HPLC [6,7,8] and electrochemical methods [9]. The purpose 
of the present study was to develop a simple, sensitive, 
accurate and precise RP-HPLC method for the determination 
of Repaglinide in rabbit plasma.  
 
MATERIALS AND METHODS  
Materials  
Repaglinide (98.3% purity), chemically, (s)-2-ethoxy-(1-[2-
[[3-methyl-1-[2- (1-piperidinyl) phenyl] butyl] amino]-2-
oxoethyl] benzoic acid, were kindly supplied by aurobindo 
Pharma Ltd (hyd, India). De-ionized water obtained from a 
Millipore-Q water purification system (Millipore®, Mumbai). 
Methanol (RFCL limited, New Delhi, India), Lichrosolv® 
water, Lichrosolv® acetonitrile for chromatographic 
separations, were obtained from Merck (Merck, Mumbai, 
India). Solvent and sample filtrations were done by using 
Ultipor® N®66 0.2 µm for and 0.45 µm membranes, 
respectively. 
Instrumentation  
The shimadzu UFLC system consists of following 
components: Prominence® CBM-20A controller, gradient 
system with dual pumps LC-10 AT VP, SPD-10 A VP detector 
with Class-VP: V6.13 software with BDS Hypersil® column, 
C-18, 150mm×4.6mm i.d., particle size 5µm (Thermo® 
scientific, India) was used at fixed wave length 254nm. 
Sonicator was used for solubility and de-aeration (PCI 
analytics, Mumbai, India). Centrifuge was from REMI®, 
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Mumbai, India. Waters symmetric® C18, i.d. 4.6×250 mm, 5 
µm   was used for check the accuracy of proposed method. 
Chromatographic conditions  
The column was equilibrated for at least 45min with mobile 
phase consists of acetonitrile: phosphate buffer pH 4.0 
(60:40) with 1% triethylamine. It was sonicated before the 
equilibration of column for 20min and followed by filtered 
through 0.2µm whatman membrane. Gradient elution 
technique was applied, and flow rate was 0.8ml/min at fixed 
wavelength at 254nm.  
Preparation of standard  
Stock solutions were prepared by dissolving appropriate 
concentration repaglinide, in methanol to yield a final drug 
concentration of  550 µg/ml of repaglinide. Working 550, 
440, 330, 220,110 µg/ml repaglinide was prepared by 
dilution of 550 µg/ml standard solution.   
Extraction procedure  
The extraction of plasma samples using the following 
procedure: First, 200 μl of plasma sample was pipetted out 
into a 1.5 ml Eppendorf tube; thereafter, mixture of working 
standard solutions and 50.0 μl of ethyl acetate and 10.0 µl of 
0. 1N Hcl was added. repaglinide is insoluble in water, it has 
two pKa values due to zwitterionic behavior, and addition of 
hydrochloric acid gives ionization, results in improvement of 
water solubility. Due to hydrophobicity of the repaglinide, 
and it was impossible to dissolve directly into plasma. To the  
standard stock solutions, the subsequent plasma addition 
can cause protein precipitation, protein precipitation results 
in poor precision of analytical method. The mixture was 
vortex and 1.00 ml of methanol: phosphate buffer pH 4.0 was 
added. The mixed solution vortexes again subsequently 
centrifuged for 15 minutes at 10,000 g.The supernatant 
present after centrifugation was transferred to a 1.5 ml 
Eppendorf tube, and evaporated to dryness at 65 ºC for 90 
min. The dried sample was reconstituted in 200 μl of the 
mobile phase prior to analysis.  
Method development   
BDS Hypersil® column was equilibrated and tested by using 
methanol/water mixture at various compositions and flow 
rate at 1ml/min. Results in broad peaks with poorer 
resolution, then switched to methanol/potassium 
dihydrogen phosphate buffer, gives less broader peaks than 
first one at different ratios. To optimize the separation, 
different fractions of acetonitrile and water tested, and 
optimum separation was obtained using 60% acetonitrile 
and 40% phosphate buffer pH 4 at flow rate10 of 0.8 ml/min 
at fixed wavelength of 254 nm.   
Method validation   
Once the chromatographic method was developed, it must be 
validated to check the efficiency of proposed method with 
USP guidelines to determine the assay, linearity, accuracy, 
precision, sensitivity, specificity and recovery.  
Calibration curve  
Standard combinations of solutions were prepared by serial 
diluting with phosphate buffer pH 4. The linearity was 
determined between the 55-550 ng/ml for repaglinide daily 
constructed by repeated analysis for five times (n=5) and 
continued for three days (n=15).   
Recovery, Precision, Accuracy   
Recovery studies were conducted for extracted samples by 
applying the least square regression analysis for peak areas 
vs. concentrations. The standard solutions were covering the 
linearity between 55-550 ng/ml for repaglinide Each sample 
injected for five times. Accuracy was determined by injecting 
three samples of standard solutions were in the range of 
50%, 100% and 150% of repaglinide for five times, by the 
same operator, same day and same equipment and by the 
different column to check specificity of analytical method.   
Specificity and selectivity   
The specificity of repaglinide retention times were 
investigated by repeated analysis. The interferences of 
endogenous compounds were identified and resolved in 
combination with sulphonylureas like gliclazide, glipizide, 
thiazolidinediones like pioglitazone. Non-sulfonylureas like 
nateglinide and mitiglinide were used in combination with 
metformin in the treatment of type II diabetes mellitus in five 
different blank plasma samples.  
RESULTS AND DISCUSSION  
Chromatogram  
The retention times and capacity factors was at 7.4 ±0.15, 
4.35±0.04 for repaglinide.  
Linearity  shown in fig 1. 
 
Fig.1 chromatogram of repaglinide in rabbit plasma 
The chromatographic analysis of repaglinide exhibited 
excellent regression values R2=0.9995 over the 
concentration range of 55-550 ng/ml for repaglinide . The 
three day daily analysis of five samples, resulting in the 
calibration curves were don’t have a statistical significant in 
values of slope, regression and intercepts.  
The assays showed the acceptable precision in the terms of 
%RSD, <5 for repaglinide.  
Recovery, precision and accuracy  
Recoveries of repaglinide from extraction samples are 95% 
(n=5). The precisions of intraday analysis of five samples 
were in the terms of %RSD on the range over 0.26-0.78% for 
repaglinide in table 1. The inter-day analysis on three 
consequent days resulted in the range of 1.30-1.56 % for 
repaglinide. The accuracy of proposed method was checked 
by using different column on intra-day and inter-day assays 
were shown in table 1for  repaglinide. 
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Table.1: Accuracy and precision of repaglinide in rabbit plasma samples 
BDS Hypersil® column C18 Waters symmetric® column C18 
Intra-day 
(µg/mL) 
Experiment 
(µg/mL) ± 
SD* 
Accuracy 
(%) 
Precision 
(%RSD)* 
Experiment 
(µg/mL) ± SD* 
Accuracy 
(%) 
Precision 
(% RSD)* 
n 
2.75 2.72±0.02 98.91 0.78 2.73±0.014 99.27 0.51 05 
5.50 5.48±0.01 99.64 0.26 5.45±0.035 99.09 0.64 05 
8.25 8.30±0.04 100.61 0.43 8.23±0.014 99.75 0.17 05 
Inter-day (µg/mL) 
2.75 2.69±0.04 97.82 1.56 2.69±0.042 97.81 1.57 15 
5.50 5.39±0.08 98.00 1.43 5.16±0.240 93.81 4.55 15 
8.25 8.10±0.11 98.18 1.30 8.01±0.169 97.09 2.10 15 
*SD=Standard Deviation, %RSD=Percentage Relative Standard Deviation 
 
Specificity and selectivity  
The blank serum showed that no interference of endogenous 
and administered substance for elution on run time. The 
retention times were different for them not detected in the 
present chromatogram. 
Limit of detection (LOD) and limit of quantitation (LOQ)  
The LODs of repaglinide was 18.15ng/ml respectively. LOQ 
of repaglinide was 55ng/ml respectively11.   
CONCLUSION  
Highly sensitive and specific analytical method was 
developed and validated for quantification of repaglinide in 
rabbit plasma samples. This analytical method was 
applicable to study of pharmacokinetic parameters in the 
research study of novel drug delivery systems in rabbit as an 
animal model. The specificity of this method was tested in 
five different sources, were analyzed. The chromatogram of 
fig.1 shows about retention times of  7.4 for  repaglinide . 
The current described HPLC method in rabbit plasma for 
repaglinide can be readily used for determination of 
pharmacokinetic parameters of novel drug delivery systems. 
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